J&J has reaped the final harvest of Phase III data it is taking to regulators in search of a blockbuster approval for their psoriasis contender guselkumab.

J&J is widely expected to use this latest batch of reliably positive data to clean up on major approvals at the FDA and EMA. But its favorable late-stage comparisons with Humira may not count for so much these days, as the pharma giant is bringing up the rear of a parade of new drugs that got to the market first.

Novartis Cosentyx got out ahead 18 months ago and the Swiss pharma giant has followed with 4-year data tracking a solid success 43.5% in keeping skin cleared over the long haul. Eli Lilly backed its new drug Taltz in a major campaign last fall. And then Valeant ambled across the finish line with brodalumab now dubbed Siliq two weeks ago. Their drug, picked up at a discount from a disappointed AstraZeneca, also comes with a black box warning on suicidal thinking that will almost certainly squeeze its slice of the market down to a sliver.

Now comes J&J, a global powerhouse, with a contender it believes is already positioned for success.

As we saw in the first Phase III, VOYAGE 1, guselkumab handily outscored a placebo on two measures of complete or near-complete skin clearance in VOYAGE 2. And once again their IL-23 drug slapped aside Humira, with guselkumab versus adalimumab achieving an IGA 0/1 score of 84% versus 67.7% and a PASI 90 of 70% compared to 46.8%, respectively.

The results were remarkably similar, which is what you want to see, Philippe Szapary, VP for dermatology and gastroenterology in J&Js Immunology Clinical Development unit, tells me about his Phase III studies.Its very reassuring to see such amazing consistency.

J&Js third Phase III study looking at patients transferred to guselkumab after an inadequate response to their other psoriasis drug Stelara also looked good. The statement notes:

Patients who switched to guselkumab consistently showed greater improvement in their psoriasis between weeks 28 and 40, compared with patients who continued to receive Stelara, having twice as many office visits with at least a 2 point improvement in IGA from week 16, the studys primary endpoint, and an IGA score of 0 or 1.

J&J gained a new approval for Stelara last fall, adding Crohns to the label as the company looked to keep its performance in blockbuster territory. The new Navigate study also positions J&J to keep about 30% of psoriasis patients who dont respond well to Stelara in the fold, so to speak.

Investigators also reaped a satisfying profile on safety, with a somewhat better set of data on adverse effects compared to Humira, which remains a big player in this field as AbbVie continues to fight off biosimilar competition. There is also one more psoriasis drug waiting in the wings. Sun Pharma gained control of Mercks MK-3222, but it isnt expected to hit the market anytime soon.

The next step is to keep gathering data with extension studies that will take the 1800 patients enrolled for VOYAGE 1 and 2 out about five years. With a target lying upstream of IL-17 and TNF, he adds, investigators are hopeful that guselkumab will continue to perform well against competition long after it arrives on the market.

More:

J&J may be late to the psoriasis drug market party, but it's planning to make a splash with guselkumab - Endpoints News

Outstanding Educator in Psoriatic Disease, Joel M. Gelfand, M.D., MSCE.Joel M. Gelfand is Professor of Dermatology and of Epidemiology at the University of Pennsylvania. He is a board-certified dermatologist whose clinical work focuses on general dermatology and psoriasis. He has created a multi-disciplinary approach to the care of psoriasis patients at Penn through his recruitment and mentoring of a rheumatologist and cardiologist who now specialize in systemic complications of psoriasis.

Outstanding Physician-Clinician, Alexa Boer Kimball, M.D., M.P.H Alexa Boer Kimball, M.D., M.P.H. is the president and chief executive officer of Harvard Medical Faculty Physicians, an academic multi-specialty group employing more than 1,200 full-time Harvard Medical School faculty members and 450 physicians in the community. She is also President of the Beth Israel Deaconess Care Organization Physician LLC, which maintains a membership of approximately 2500 physicians, and a Professor of Dermatology at Harvard Medical School.

Dr. Kimball is an international expert on psoriasis and hidradenitis suppurativa who has published more than 250 peer-reviewed scientific papers and 100 Questions and Answers about Psoriasis, which has been translated into Spanish, Greek and Korean. In 2016 she was named Mentor of the Year by the Women's Dermatologic Society.

Health Professional Volunteer of the Year Craig F. Teller, MDCraig F. Teller, MD, is a native Houstonian and has been practicing dermatology since 1995. Board certified by the American Board of Dermatology and a fellow of the American Academy of Dermatology, Dr. Teller holds an academic appointment as Clinical Instructor of Dermatology in family medicine at Baylor College of Medicine as well as Clinical Instructor of Dermatology at the University of Texas Medical School in Houston. Dr. Teller is being recognized for his efforts and promotion of the NPF mission and key initiatives at the local division with strong contributions and support of the overall NPF goals and objectives.

Outstanding Allied Health, Lakshi Aldredge, MSN, ANP-BCMs. Lakshi Aldredge is a nurse practitioner who has practiced at the Portland VA Medical Center for the past 22 years, the last eight years in the medical Dermatology Service. Aldredge is being recognized for her outstanding achievements in improving psoriatic disease clinical practice and the quality of life of her patients. She is actively involved in the day-to-day clinical care of her patients and is nationally known for her exceptional clinical knowledge and expertise.

Aldredge is the past President of the national Dermatology Nurses' Association (DNA) and is the current Chair of the Nurse Practitioner Society of the DNA. She is on the Advisory board of Dermatology World, is an Associate Editor of Psoriasis Forum, the peer-reviewed journal of the National Psoriasis Foundation, as well as a member of the Editorial Board of the Journal of the Dermatology Nurses' Association.

Over the last 50 years, the National Psoriasis Foundation (NPF) has become the world's leading nonprofit patient advocacy organization fighting for individuals with psoriasis and psoriatic arthritis. NPF leads this fight by driving efforts for a cure and improving the lives of the more than 8 million Americans affected by this chronic disease. To date, NPF has funded more than $15 million in research grants and fellowships, and to commemorate 50 years, NPF plans to raise an additional $2 million for early scientific career research programs in 2017 alone. Each year, NPF strives to support, educate and advocate on behalf of more individuals living with or caring for someone with the disease than ever before. As part of that effort, NPF established the Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. Join our community today and help drive discovery and create community for all living with psoriatic disease.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/national-psoriasis-foundation-2016-medical-professional-awards-winners-300416249.html

SOURCE National Psoriasis Foundation

http://www.psoriasis.org

See more here:

National Psoriasis Foundation 2016 Medical Professional Awards Winners - PR Newswire (press release)

WEDNESDAY, March 1, 2017 (HealthDay News) -- People with autoimmune diseases -- conditions that cause a person's immune system to turn against the body -- appear to have an increased risk of developing dementia, a new British study suggests.

Researchers found that 18 out of 25 different autoimmune diseases, such as lupus, psoriasis or multiple sclerosis, "showed a statistically significant association with dementia," said study co-author Dr. Michael Goldacre. He's a professor of public health at the University of Oxford.

But Goldacre and other experts stressed that the study didn't prove that autoimmune diseases cause dementia. The research only showed that these conditions are associated with a higher risk of dementia.

Specifically, the study found that people with multiple sclerosis appeared to have nearly double the risk of dementia. Psoriasis was associated with a 29 percent increased risk of dementia. Lupus was linked to a 46 percent increased risk, and rheumatoid arthritis with a 13 percent increased risk. Crohn's disease was associated with a 10 percent increased risk.

"How do [autoimmune diseases] affect the brain? We don't know, although others have suggested that chronic inflammation, possibly autoimmune effects, or possibly both, may have a role in Alzheimer's," Goldacre said.

For this study, the researchers reviewed information from more than 1.8 million people in England. All had been admitted to a hospital with an autoimmune disease between 1998 and 2012.

Compared with people admitted for other causes, patients admitted for treatment of an autoimmune disorder were 20 percent more likely to wind up back at the hospital later with dementia, the researchers found.

However, when researchers broke down their findings by type of dementia, they found that autoimmune diseases only increased the risk of Alzheimer's disease by about 6 percent.

The autoimmune diseases had a much stronger impact on the risk of vascular dementia. The risk of vascular dementia was 28 percent higher in people with autoimmune diseases. People with vascular dementia experience a decline in their thinking skills due to conditions that block or reduce blood flow to the brain, starving brain cells of oxygen and nutrients.

This apparent increased risk for vascular dementia could be caused by the effect of autoimmune diseases on the circulatory system, the researchers said. The study also found that people with an autoimmune disease were 53 percent more likely to be hospitalized for heart disease. Those with an autoimmune disease were also 46 percent more likely to have a stroke.

The link between vascular dementia and autoimmune diseases is "something new," said James Hendrix. He's the director of global science initiatives for the Alzheimer's Association, based in Chicago.

This link could implicate chronic inflammation as a potential cause of progressive dementia, he said.

Hendrix explained that a person with a sprained ankle experiences inflammation and swelling as the immune system responds to their injury. If the inflammation continues for an extended period, that person could wind up with joint damage and arthritis.

"We are starting to think neuron inflammation is similar," Hendrix said.

Both Hendrix and Goldacre noted that the study is observational, so it couldn't prove a direct cause-and-effect link. In addition, Goldacre said the size of the associations they found was small, and should be taken "more as a message for interested researchers than for interested patients."

Dr. Walter Rocca is a professor of epidemiology and neurology with the Mayo Clinic in Rochester, Minn. He said the findings are "important" but may be limited by the fact that the researchers focused solely on people admitted to the hospital with an autoimmune disorder.

"The concern is that many persons affected by an autoimmune disease may never need to be admitted to a hospital, and many persons affected by dementia may not need to be hospitalized," Rocca said.

"This incomplete capture [of information] may cause a distortion of the findings," he added.

Rocca also pointed out that the 25 autoimmune diseases considered in the study are very different from each other. For example, some attack the joints or the endocrine glands, while others -- like multiple sclerosis -- may directly affect the brain.

Findings from the study were published March 1 in the Journal of Epidemiology & Community Health.

See the original post:

Immune Disorders Such as MS, Psoriasis May Be Tied to Dementia ... - Helena Independent Record

Mark Lebwohl, MD, reviews efficacy of new biologics for psoriasis Healio ORLANDO, Fla. New biologics for psoriasis have achieved high levels of skin clearance in short-term and long-term trials that would have been unexpected a few years ago, according to a presentation at the American Academy of Dermatology Annual ...

See the rest here:

Mark Lebwohl, MD, reviews efficacy of new biologics for psoriasis - Healio

New Delhi: Psoriasis, a skin condition in which skin cells build up and form scales and itchy, dry patches, has high chances of recurrence if the patient is subject to anxiety and depression, say doctors.

According to the doctors, stigma attached to the skin disease also contributes towards its recurrence. Nearly 84 per cent people suffering from moderate-to-severe psoriasis face discrimination and humiliation, with at least 40 per cent of them witnessing unwelcoming glares in public spaces.

Psoriasis has a significant impact on a patients quality of life. As long as there is a stigma attached to these conditions, patients will continue to have flare ups induced by emotional distress as anxiety and depression are major causes of psoriasis recurrences, Rajiv Sekhri, Consultant Dermatologist at Fortis hospital said on Wednesday.

The doctors also said that at least 18 per cent of the patients have been frequently asked whether their condition is communicable, pointing to a grave lack of awareness on the disease.

Psoriasis is a skin condition that changes the life cycle of skin cells. It causes cells to build up rapidly on the surface of the skin. The extra skin cells form thick, silver scales and itchy, dry, red patches that are sometimes painful. It is a persistent, long-lasting disease.

Stating that the psoriasis can affect personal lives and mental health, Sekhri said a survey conducted last year showed 36 per cent people admitted to feeling ashamed of their skin and the way they look.

Forty eight per cent of the patients interviewed shared that psoriasis has impacted their professional life and 30 per cent of them feel that psoriasis has impacted past or current relationships. These results reflect lack of hope and self-esteem, with 31 per cent of people stating that they do not believe clear or almost clear skin is an achievable goal for them, said Sekhri quoting the global survey of 8,300 people with psoriasis.

Sonal Soin, Medical Director and founder of city based Aayna Clinic said that awareness as well as acceptance is very low for psoriasis among patients as well as society.

Most of the people think it is contagious and avoid shaking hands or eating with patients suffering from the condition. Psoriasis is not contagious, one cannot pass the skin condition from one person to another, she said.

Creating awareness about psoriasis can help improve the quality of life of psoriasis patients, Soin added.

Read the rest here:

'Psoriasis likely to recur if patients have anxiety, depression' | The ... - The Siasat Daily

STELARA (ustekinumab) is a prescription medicine that affects your immune system. STELARA can increase your chance of having serious side effects including:

STELARA may lower your ability to fight infections and may increase your risk of infections. While taking STELARA, some people have serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.

You should not start taking STELARA if you have any kind of infection unless your doctor says it is okay.

After starting STELARA, call your doctor right away if you have any symptoms of an infection (see above).

STELARA can make you more likely to get infections or make an infection that you have worse. People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL12) and interleukin 23 (IL23) are at a higher risk for certain serious infections that can spread throughout the body and cause death. People who take STELARA may also be more likely to get these infections.

STELARA may decrease the activity of your immune system and increase your risk for certain types of cancer. Tell your doctor if you have ever had any type of cancer. Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving STELARA. Tell your doctor if you have any new skin growths.

RPLS is a rare condition that affects the brain and can cause death. The cause of RPLS is not known. If RPLS is found early and treated, most people recover. Tell your doctor right away if you have any new or worsening medical problems including: headache, seizures, confusion, and vision problems.

Serious allergic reactions can occur. Stop usingSTELARA and get medical help right away if you have any symptoms such as: feeling faint, swelling of your face, eyelids, tongue, or throat,chest tightness, or skin rash.

Tell your doctor about all the medicines you take, including prescription and overthecounter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

When prescribed STELARA:

Common side effects of STELARA include: upper respiratory infections, headache, and tiredness in psoriasis patients; joint pain and nausea in psoriatic arthritis patients; and upper respiratory infections, redness at the injection site, vaginal yeast infections, itching, urinary tract infections, and vomiting in Crohns disease patients. These are not all of the possible side effects with STELARA. Tell your doctor about any side effect that you experience. Ask your doctor or pharmacist for more information.

Please read the full Prescribing InformationandMedication Guidefor STELARAand discuss any questions you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1800FDA1088.

Requires AdobeReader. Click here to download

061408-161010

Read more:

Psoriasis Treatment Options | STELARA (ustekinumab)

LONDON, Feb. 28, 2017 /PRNewswire/ --

Details Psoriasis Drugs Your Guide to R&D, Opportunities and Potential Revenues What does the future hold for treating psoriasis? Visiongain's new report gives you multilevel revenue forecasts from 2016, helping you stay ahead in data. There you see financial results, R&D trends, opportunities and potential revenues.

Download the full report: https://www.reportbuyer.com/product/4031803/

In our study you examine predicted sales to 2026 at overall world market, submarket, product and national level. You also assess technologies, competitive forces and expected products. That work's purpose is to help you avoid falling behind in knowledge, missing business or losing influence.

So read on now to explore that industry and discover what its future market could be worth. See how our investigation can benefit your work.

Forecasts from 2016 to 2026 and other analyses to help you harness opportunities Why miss data you need? Why struggle to find it? Instead let our analysis guide you through the psoriasis drug market's present and future. That understanding could bring you quicker, easier results, also benefiting your influence and reputation for business insight.

Besides revenue forecasting to 2026, our new work shows you recent results, growth rates and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). In our 169 page study you gain 74 tables and 63 charts to benefit your research, analyses, plans, decisions and presentations.

The following sections outline what you get in our updated investigation.

Sales predictions for the world market and submarkets What is that industry's potential? Discover in our report overall world revenue to 2026 for psoriasis-treating medicines. First you see individual revenue forecasts to 2026 for three main submarkets at world level: - Biological drugs - Topical treatments - Small-molecule systemic therapies.

How will those segments' revenues expand? Which classes of treatment will generate most sales? There you assess prospects for revenue growth, seeing where you can gain, assessing how that industry will compete and develop.

You find revenue predictions by product, too, seeing from 2016 how they can succeed.

Revenue predictions for 13 products to 2026 discover what their futures hold How will individual drugs perform from 2016 to 2026 at world level? Our report forecasts revenues of established brands and medicines expected from 2016.

In our work you assess 13 drugs, including these brands: - Humira (adalimumab) - Stelara (ustekinumab) - Enbrel (etanercept) - Remicade (infliximab) - Otezla (apremilast)

There you discover how high sales can go, to 2026, finding drugs and years with highest predicted growth and revenues. You also examine trends and competition. You see what is happening, understanding challenges, progress, competitors and opportunities.

You find geographical revenue predictions too.

National markets where will highest revenues and growth occur? In developed and developing countries, opportunities in psoriasis treatment will occur from 2016. You see where and how pharma companies can develop and gain.

Our analyses show individual revenue forecasts to 2026 for these 11 national markets: - US and Japan - France, Germany, Italy, Spain and UK - Brazil, Russia, India and China.

There you find countries with highest revenues and potential sales growth. You assess that technology's future, seeing progress and finding what it means, including emerging trends for those skin disorder treatments.

Events affecting developers, producers and sellers issues shaping that industry Our report explains forces affecting that industry and market from 2016, including these influences: - Research and development, including monoclonal antibodies, IL-12, IL-17, IL-23, PDE4, TNF, JAK and T-cell inhibition, and histamine receptor antagonism - Prevalence of that skin disease, as well as issues for patients and healthcare providers assess treatment needs - Competition from generic drugs, biosimilars and new biologics - Companies specialising in dermatology and autoimmune disorders explore capabilities and emerging trends to treat psoriasis - Advances in drug delivery to benefit companies, patients and payers, including lotion, ointment and foam.

In our survey you explore political, economic, social and technological questions, assessing outlooks for business. You also examine that pharmaceutical segment's strengths, weaknesses, opportunities and threats.

That way you discover what the present and future hold, seeing what is possible for those drug developers, producers and marketers. Stay ahead in knowledge.

Companies leading that industry and our overall revenue prediction for 2020 From 2016, treatments for psoriasis hold potential for investments, medical advances and higher revenues. Our work predicts the overall world market for psoriasis medicines will reach $11.4bn in 2020, with further expansion to 2026.

See what is possible there the expected gains. Our report shows you what technologies and firms hold greatest potential. You explore activities of these companies, among others: - Johnson & Johnson - AbbVie - Amgen - Pfizer - Novartis - Celgene - LEO Pharma.

Our analysis shows you participants' results, capabilities, developments and outlooks. R&D in that industry is strong. From 2016 the psoriasis market holds many opportunities for revenue growth. Our work explains that potential, helping you stay ahead in knowledge.

Main ways Psoriasis Drugs Market Forecasts 2016-2026 helps your work In particular our new investigation gives you these advantages to benefit your research, analyses, decisions, proposals and presentations: - Revenues to 2026 at world level, with forecasting of 3 submarkets and 13 products assess prospects for investments and sales growth - Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia investigate leading countries for revenues and expected sales - Forces driving and restraining that industry's expansion discover what influences revenue gain, finding trends, developments and opportunities - Prospects for established competitors and rising companies explore companies' portfolios, results, R&D and outlooks for future success.

Information found nowhere else: see how you can gain why miss out? Our investigation gives you independent analysis. There you gain business intelligence found only in our work, finding where opportunities for revenue expansion exist.

See in our work how you could benefit your research, analysis and decisions. Explore progress and possibilities. Also find how you could save time and benefit your authority on those drugs, helping your reputation for commercial insight.

Medicines for psoriasis get revenue predictions now, seeing what the future holds Our new report is for everyone investigating drugs for inflammation and skin disorders. In our survey you explore revenue forecasts to 2026, with discussions and other data. Avoid missing out in knowledge instead please get our report here now. Download the full report: https://www.reportbuyer.com/product/4031803/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/psoriasis-drugs-market-forecasts-2016-2026-300414898.html

Read this article:

Psoriasis Drugs Market Forecasts 2016-2026 - Yahoo Finance

PORTLAND, Ore., Feb. 28, 2017 /PRNewswire/ -- This year, the National Psoriasis Foundation (NPF) celebrates 50 years of patient support, advocacy, research funding, education and outreach to the more than 8 million individuals living with psoriasis and psoriatic arthritis. Originally formed in 1966 as The Psoriasis Society of Oregon, and officially becoming the National Psoriasis Foundation in 1967, its mission is focused on driving efforts to cure psoriatic disease and dramatically improving the lives of those affected.

Throughout its first 50 years, NPF has made significant contributions in advancing the research of life-changing treatments that have helped millions of people. From the tar-based procedures and topical creams to the revolutionary biologic treatments that exist today, NPF has always supported innovative approaches to treating psoriasis and psoriatic arthritis. While these achievements are to be celebrated, there is still much work to be done to improve access to treatments and, ultimately, to find a cure.

"We have only scratched the surface of what could be possible in treatingand ultimately curingpsoriasis and psoriatic arthritis. Advancements in psoriatic disease research are happening all the time, and NPF remains committed to funding this research while offering programs and services that support even more patients," said Dr. Colby Evans, M.D., National Psoriasis Foundation board chair. "I am honored to be associated with an organization that has always been at the forefront of driving efforts to find a cure for psoriasis and psoriatic arthritis."

NPF has achieved many milestones over the past 50 years, including securing for the first time ever, line-item funding in a federal budget for skin disease research, successfully lobbying the U.S. Food & Drug Administration for the approval of methotrexate for the treatment of severe psoriasis and opening the world's first support center providing free personalized assistance for people with psoriatic disease. Most recently, members of the NPF Medical Board issued the first paper in the United States that outlines psoriasis treatment targets and goals for individuals and health care providers to work on together to achieve clear skin and ultimately reduce the burden of the disease.

"NPF has been a pioneer in supporting research efforts that have led to the groundbreaking treatments used today," said Randy Beranek, president and CEO of the National Psoriasis Foundation. "During our 50th year, we are excited to recognize the people and milestones that have contributed so much to the psoriatic disease community, and remain committed to supporting research efforts towards finding a cure and dramatically improving the health outcomes of all affected by psoriasis and psoriatic arthritis."

In remaining true to its mission, the theme of the NPF 50th Year Celebration is "Driving Discovery, Creating Community." This allows the Foundation to celebrate the achievements of the past 50 years and to recognize the individuals and milestones that have made significant contributions to the psoriatic disease community. To recognize its 50th year, NPF will be holding events throughout the year, starting with a formal celebration on June 8, 2017, at the Plaza Hotel in New York City, and followed by the National Volunteer Conference and Research Symposium August 4 6, 2017 in Chicago, IL, as well as various TeamNPF events across the country.

Read More

During this year of celebration, NPF is committed to raising $2 million to fund several promising areas of research and programing, specifically early career research. Supporting the NPF 50th year campaign will ensure that researchers studying psoriatic disease will have the resources needed to turn their questions and theories into a cure.

To learn more about the NPF 50th Year Celebration and how to get involved, visit: https://www.psoriasis.org/NPF50th.

Over the last 50 years, the National Psoriasis Foundation (NPF) has become the world's leading nonprofit patient advocacy organization fighting for individuals with psoriasis and psoriatic arthritis. NPF leads this fight by driving efforts for a cure and improving the lives of the more than 8 million Americans affected by this chronic disease. To date, NPF has funded more than $15 million in research grants and fellowships, and to commemorate 50 years, NPF plans to raise an additional $2 million for early scientific career research programs in 2017 alone. Each year, NPF strives to support, educate and advocate on behalf of more individuals living with or caring for someone with the disease than ever before. As part of that effort, NPF established the Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. Join our community today and help drive discovery and create community for all living with psoriatic disease.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/national-psoriasis-foundation-celebrates-50-years-of-patient-support-advocacy-research-education-and-outreach-300414766.html

Excerpt from:

National Psoriasis Foundation Celebrates 50 Years of Patient Support, Advocacy, Research, Education and Outreach - Yahoo Finance

Lina Eliasson,1 Anthony P Bewley,2 Farhan Mughal,3 Karissa M Johnston,4 Andreas Kuznik,5 Chloe Patel,1 Andrew J Lloyd1

1Clinical Outcomes Assessment, ICON Clinical Research UK Ltd, 2Department of Dermatology, Whipps Cross University Hospital, Barts Health National Health Service Trust, London, 3Health Economics Outcomes Research, Celgene Ltd, Uxbridge, UK; 4Epidemiology, ICON Commercialisation and Outcomes, Vancouver, BC, Canada; 5Global Health Economics and Outcomes Research, Celgene Corporation, Summit, NJ, USA

Objective: Treatment options for psoriasis offer trade-offs in terms of efficacy, convenience, and risk of adverse events. We evaluated patients preferences with respect to benefitrisk in the treatment of psoriasis. Methods: A discrete choice experiment was conducted in adults from the UK with moderate-to-severe psoriasis using an orthogonal design with 32 hypothetical choice sets. Participants were randomly assigned to one of two surveys with 16 choice sets. Patients preferences were investigated with respect to the following attributes: reduction in body surface area affected by psoriasis, treatment administration (frequency and mode of delivery), short-term diarrhea or nausea risk, and 10-year risk of developing melanoma or nonmelanoma skin cancer, tuberculosis, or serious infections. A mixed effects logistic regression model generated relative preferences between treatment profiles. Results: Participants (N=292) had a strong preference to avoid increased risk of melanoma or nonmelanoma skin cancer (odds ratio [OR]: 0.44 per 5% increased 10-year risk) and increased risks of tuberculosis and serious infections (both ORs: 0.73 per 5% increased 10-year risk) and preferred once-weekly to twice-daily tablets (OR: 0.76) and weekly (OR: 0.56) or fortnightly (OR: 0.65) injections. Participants preferred avoiding treatments that may cause diarrhea or nausea in the first 2 weeks (OR: 0.87 per 5% increase) and preferred treatments that effectively resolved plaque lesions (OR: 0.93 for each palm area still affected). Conclusion: All attributes were significant predictors of choice. Patients preference research complements clinical trial data by providing insight regarding the relative weight of efficacy, tolerability, and other factors for patients when making treatment choices.

Keywords: benefit, discrete choice experiment, patients preferences, psoriasis, risk, treatment

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Here is the original post:

Evaluation of psoriasis patients' attitudes toward benefitrisk and therapeutic trade-offs in their choice of treatments - Dove Medical Press

Home Skin Health Home remedies to soothe your psoriasis

Psoriasis is a skin disorder that causes the epidermis to become covered in raised, red, itchy plaques that are spotted with white scales. It most commonly occurs on the knees, elbows, and scalp, but may also affect your torso, palms, and the soles of your feet. These plaques are sometimes itchy and painful, and may even crack and bleed, making the condition both uncomfortable and unsightly. While there are medications available to help soothe the symptoms of psoriasis, some may prefer a simpler home remedy. Continue reading to discover some of the most common and effective home remedies for treating psoriasis.

Heavy cream. Use a thick moisturizer or petroleum jelly to lock in moisture to the affected areas. Hydrating your skin with a heavy-duty salve can help relieve the itchiness associated with dry, scaly patches.

Apple cider vinegar. If your scalp is affected by psoriasis, you may be wary of slathering a cream over it for fear of making your hair limp and greasy. So long as the skin of your scalp is not bleeding or cracked, you can rub apple cider vinegar over it to soothe the itch. This is best done before a shower, as once the vinegar dries, you should rinse it out to avoid any further irritation.

Sun. The suns rays can actually help fight psoriasis, so head out into the sunshine for a few minutes daily and get your fill. Be sure to use sunscreen on the areas of your body not affected by the skin disorder to prevent sun damage that may lead to skin cancer.

Epsom salts. Sprinkle some Epsom salts into a warm bath and soak for about 15 minutes. The salts will help rid your body of the silvery scales and soothe any itching. Pat yourself dry after stepping out of the tub and be sure to moisturize in order to lock in all that moisture and keep your skin hydrated.

Oats. An oat bath is also a great way to soothe dry, itchy skin. Mix some ground-up oats into your warm bath water, then relax in the tub and let this natural remedy work its magic. Just as you would after an Epsom salt bath, ensure you moisturize afterward to seal in the hydration.

Meditation and yoga. Stress can exacerbate your condition, so partaking in activities like yoga and meditation to help manage it may also reduce your symptoms. This is especially true for those with psoriatic arthritis, as yoga can help alleviate your joint pain and reduce itchy flare ups.

Aloe Vera. Aloe Vera gel is a go-to to soothe sunburns, but its cooling and anti-inflammatory properties have also been found to ease the symptoms of psoriasis. The gel can help reduce redness and get rid of the irritating itch.

Psoriasis is an irritating condition that leaves your skin sore and itchy, and while there are some medications on the market to help treat it, there are also a few tried and true home remedies to ease your symptoms. Next time you experience a flare-up, try reaching for the apple cider vinegar or Epsom salts to rid yourself of the discomfort, and be sure to moisturize your skin daily.

Related: Psoriasis diet: What foods to eat and what foods to avoid?

Related Reading:

Psoriasis skin inflammation treatments improve heart disease symptoms: Study

Treating psoriasis reduces risk of other ailments: Study

http://www.webmd.com/skin-problems-and-treatments/psoriasis/ss/slideshow-home-remedies-for-psoriasis

Original post:

Home remedies to soothe your psoriasis - Bel Marra Health

In 2013, the Centers for Disease Control and Prevention led a collaborative effort to develop the first-ever public health agenda for psoriasis and psoriatic arthritis. Their agenda was published in the American Journal of Preventative Medicine.

A public health approach to psoriatic diseases will allow scientists to better identify possible environmental contributions, which could potentially help us stop these diseases before they start, Andrew D. Robertson, chief scientific and medical officer for the National Psoriasis Foundation, stated in a post by the Foundation.

Read:Psoriasis Facts And Myths: 5 Things To Know About Misunderstood Immune Disease

Psoriasis is a chronic autoimmune disease that causes patches of red, scaly skin. About 10to 20 percentof people with psoriasis will develop an inflammatory type of arthritis known as psoriatic arthritis, according to the CDC. It causes your joints to become painful, swollen, and warm to the touch.

These are eights signs you may be at risk for psoriatic arthritis:

1. You have psoriasis.The majority of those with psoriatic arthritis developpsoriasis first.

2. Youre overweight.Although research is still growing, there's been findings associating being overweight and having psoriasis and psoriatic arthritis.

3. You have psoriasis in your nails. Of the patients with both psoriasis andpsoriatic arthritis, approximately 80 percenthave nail disease, research published in the Journal of the European Academy of Dermatology and Venerology reports.

4. You were young when diagnosed with psoriasis.Children are more likely than adults to experience the onset of psoriasis andpsoriatic arthritis simultaneously, the National Psoriasis Foundation reports.

5. You have a family member with psoriatic arthritis and you also have psoriasis. Genetic factors are important forpsoriatic arthritis risk, but the research is ongoing regarding exactly which genes are responsible.

6. You have an injury.Physical trauma may be associated with triggeringpsoriatic arthritis among those with psoriasis, astudy concludes.

7. You have had strep throat.Common infections, such as strep throat, may be a trigger forpsoriatic arthritis flare-ups, Healthline reports.

8. You have HIV.Those with the immunodeficiency disorder are more likely to havepsoriatic arthritis. Psoriatic arthritis may precede the detection of HIV infection, according to the American College of Rheumatology.

Although psoriatic arthritis typically occurs in people who have psoriasis, it still can affect those who dont have the disease. Theres currently no cure for psoriatic arthritis, but treatments including nonsteroidal anti-inflammatory drugs, immunosuppressants, and steroid injections, among other inflammation control methods may help to prevent joint pain and disability, according to Mayo Clinic.

See more:Psoriasis Associated with Higher Odds of Having One of 14 Autoimmune Diseases

Psoriasis Treatment: 5 Natural Ways To Alleviate The Skin Disorder At Home

The rest is here:

Psoriatic Arthritis: 8 Signs You May Be At Risk For The Autoimmune Disease - Medical Daily

Psoriasis is a chronic autoimmune condition that causes the rapid build-up of skin cells. This build-up of cells causes scaling on the skins surface.

Inflammation and redness around the scales is fairly common. Typical psoriatic scales are whitish-silver and develop in thick patches. Sometimes, these patches will crack and bleed.

People with psoriasis may find living with the condition challenging.

Here are four tips on how to cope with psoriasis:

1. UPDATING MAKE-UP

Daily cosmetic products could be worsening skin irritation and redness. Clients should look for fragrance-free, hypoallergenic and non-clogging moisturisers to support skin with an extra layer of protection.

Primers will give users a smoother skin surface to work with, and liquid foundation can be easily controlled with any skin type.

As for removing make-up, petroleum-based make-up removers loosen make-up prior to taking it off and can help avoid aggravating sensitive spots.

2. EATING HEALTHY

Controlling diet can be beneficial for individuals with psoriasis as some foods can cause redness and swelling of the skin. An anti-inflammatory diet has proven to help individuals manage plaque psoriasis.

Psoriasis sufferers should eat: Fish, nuts, oils, and colourful fruits and vegetables. Foods to avoid include: Nightshade vegetables, dairy, refined sugar, and red meat.

3. TAKING VITAMINS

Many people with psoriasis find that including vitamins and supplements in their diet help their skin clear.

Omega 3 helps decrease inflammation and powers the immune system through fish oil, vegetable oil, soy, nuts, and seeds.

Vitamin D can be found in salmon, Swiss cheese and sunshine, which helps slow the growth of skin cells.

4. LOWERING STRESS LEVELS

Psychodermatology is a term doctors created, linking emotional stress to skin. Bodies reacting to a mental state can trigger certain hormones to be released, which can cause skin to have negative side effects.

The brain and skin are connected because they are derived from the same cells. When people experience stress in life, quite frequently their skin becomes a reflection of the stresses.

The following can help reduce stress levels: Acupuncture, massage therapy, behavioural therapy, talk therapy, and relaxation training.

Michelle Vernon is a licensed aesthetician who operates the Body Studio Skincare located at 23 Central Plaza, Kingston 10, and Fairview Shopping Centre, Montego Bay. She may be reached at telephone 908-0438 or 684-9800; IG@bodystudioskincare; E-mail: bodystudioskincare@gmail.com; Website: http://www.bodystudioskincare.com.

Read the original:

How to cope with Psoriasis - Jamaica Observer

Everyday Health (blog)

Depression puts psoriasis patients at significantly greater risk of psoriatic arthritis Science Daily Psoriasis is a lifelong disease that is associated with significant cosmetic and physical disability and puts patients at increased risk for many major medical disorders. A multidisciplinary team of researchers at the University of Calgary, Canada ... Can Depression Up Odds for Arthritis Linked to Psoriasis?Everyday Health (blog) Psoriasis Patients Who Suffer From Depression at Higher Risk for Psoriatic ArthritisCDA News Depression raises risk of developing psoriatic arthritisOnMedica Healthcare Today all 5 news articles »

Read the original:

Depression puts psoriasis patients at significantly greater risk of psoriatic arthritis - Science Daily

Depression in people with the chronic inflammatory skin disease psoriasis increases the risk of getting the joint condition known as psoriatic arthritis by about 37 percent, new research indicates.

The finding raises concerns because depression is not uncommon in people with psoriasis, according to the authors of the study in the Feb. 22 issue of theJournal of Investigative Dermatology.

"For many years, the rheumatology and dermatology communities have been trying to understand which patients with psoriasis go on to develop psoriatic arthritis, and how we might detect it earlier in the disease course," senior investigator Dr. Cheryl Barnabe said in a journal news release. She is from the McCaig Institute for Bone and Joint Health and the O'Brien Institute for Public Health at the University of Calgary in Alberta.

While the study found a connection between depression and the development of psoriatic arthritis, it wasn't designed to prove a cause-and-effect relationship.

RELATED: 9 Ways to Manage PsoriaticArthritis Fatigue

Psoriasis is a condition characterized by red, itchy and scaly skin patches. These patches can sometimes be disfiguring. Psoriatic arthritis generally occurs in people with psoriasis, though it can occur on its own, according to the American College of Rheumatology. The condition causes joint pain and swelling, typically in the large joints and fingers and toes. It can cause joint damage, too.

The study authors noted that prior work has linked having a major depressive disorder with a high risk for systemic inflammation. This could explain why depression would bump up the risk for psoriatic arthritis.

To explore the link, the investigators analyzed information on more than 70,000 psoriasis patients in the United Kingdom that had been collected by a primary care database.

Patients were tracked for upwards of 25 years.

The researchers adjusted the data to account for other factors, such as age and drinking habits. Ultimately, they determined that people who had been depressed faced a much higher risk for psoriatic arthritis than those who hadn't been depressed.

"There is a tendency to think of depression as a purely 'psychological' or 'emotional' issue, but it also has physical effects and changes in inflammatory and immune markers have been reported in depressed people," said Dr. Scott Patten, from the O'Brien Institute.

"Depression may be a risk factor for a variety of chronic conditions, and this research is an example of how big data approaches can identify these associations," he said.

Go here to read the rest:

Can Depression Up Odds for Arthritis Linked to Psoriasis? - Everyday Health (blog)

Psoriasis is a lifelong inflammatory skin disease characterized by red, itchy, and scaly patches of skin. Those who suffer from this disease are also at increased risk for many major medical disorders, including psoriatic arthritis, a type of arthritis characterized by psoriasis plus inflammation of and around the joints.

Now a new Canadian study published in the Journal of Investigative Dermatology finds that psoriasis patients who develop depression have a 37 percent greater risk of subsequently developing psoriatic arthritis, compared with patients who do not develop depression.

For many years, the rheumatology and dermatology communities have been trying to understand which patients with psoriasis go on to develop psoriatic arthritis and how we might detect it earlier in the disease course, said lead researcher Cheryl Barnabe, M.D., M.Sc., of the McCaig Institute for Bone and Joint Health and the OBrien Institute for Public Health, Cumming School of Medicine, at the University of Calgary.

Depression is quite common among psoriasis patients. Based on recent laboratory findings showing that major depressive disorder is associated with increased systemic inflammation, the researchers hypothesized that psoriasis patients who develop depression may be at increased risk of developing psoriatic arthritis.

There is a tendency to think of depression as a purely psychological or emotional issue, but it also has physical effects and changes in inflammatory and immune markers have been reported in depressed people, commented Scott Patten, M.D., Ph.D., the OBrien Institute for Public Health, Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Cumming School of Medicine.

Depression may be a risk factor for a variety of chronic conditions and this research is an example of how big data approaches can identify these associations.

The researchers evaluated data from primary care medical records in the United Kingdom to find over 70,000 patients with a new diagnosis of psoriasis. Then they identified the patients who subsequently developed depression and those who developed psoriatic arthritis. Patients were followed for up to 25 years or until they developed psoriatic arthritis.

Their findings show that patients with psoriasis who developed major depressive disorder were at 37 percent greater risk of subsequently developing psoriatic arthritis compared with patients who did not develop depression, even after accounting for numerous other factors such as age and use of alcohol.

The research emphasizes the need for physicians who treat patients with psoriasis to actively identify and address depression. This could include rapid, effective treatment of psoriasis and psychosocial management of the cosmetic burden of psoriasis.

The findings also draw into question the biological mechanisms by which depression increases the risk for psoriatic arthritis. These mechanisms may include altered systemic inflammation as a consequence of depression, or even the role of lifestyle behaviors such as physical activity or nutrition, which are typically worsened by depression, and which may place an individual at risk for psoriatic arthritis.

It is evident to physicians who treat patients with psoriasis, that there is a significant psychological and social burden associated with this disease, which is reflected in an increase in the rates of depression, said Laurie Parsons, M.D., of the Cumming School of Medicine.

This study brings us a little closer to understanding the role of chronic inflammation as a systemic player in both the physical and psychological manifestations of psoriasis and underscores the need for closer attention to symptoms of depression in this group of patients.

Source: Elsevier Health Sciences

APA Reference Pedersen, T. (2017). Depression in Psoriasis Patients Ups Risk of Arthritis. Psych Central. Retrieved on February 24, 2017, from https://psychcentral.com/news/2017/02/23/depression-in-psoriasis-patients-ups-risk-of-arthritis/116785.html

Continued here:

Depression in Psoriasis Patients Ups Risk of Arthritis - PsychCentral.com

NEW YORK, Feb. 21, 2017 /PRNewswire/ -- Provides understanding and access to the psoriasis partnering deals and agreements entered into by the worlds leading healthcare companies.

Read the full report: http://www.reportlinker.com/p03605692-summary/view-report.html

Description The Global Psoriasis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.

- Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of partnering trends.

Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.

Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.

Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Read the full report: http://www.reportlinker.com/p03605692-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-psoriasis-partnering-2010-to-2017-300411256.html

See original here:

Global Psoriasis Partnering 2010 to 2017 - Yahoo Finance

Approximately 1.8 million people in the UK suffer with psoriasis, a chronic autoimmune skin disease. Psoriasis commonly presents in the mid 30s - but it can occur at any age.

Psoriasis is a common skin condition that causes red patches of inflamed skin with silvery-white scales, often on the elbows and knees but may occur anywhere on the body. It is often genetic and is not contagious.

ADVERTISEMENT - CONTINUE READING BELOW

Skin turnover is accelerated in those suffering from psoriasis, which causes accumulation of cells on the skin surface and leads to scaling. Psoriasis triggers include: stress, cold, dry weather and lack of adequate sun exposure, recent infection such as strep throat and upper respiratory infections, dry skin and injury to the skin such as cuts, burns, and insect bites. Certain medications can induce a psoriasis flare including anti-malarials, beta-blockers, and lithium. Smoking and excessive alcohol consumption may also exacerbate the condition.

Psoriasis can have a significant impact on the quality of life - with confidence, self-esteem and mood often being affected.

Related Article

10 body checks every woman should be doing

Whilst frustratingly there is currently no cure for psoriasis, there are a multitude of treatment options and lifestyle changes to help manage the condition to a certain degree.

We spoke to Dr Alexis Granite, Consultant Dermatologist at the Cadogan Clinic for her expert tips to help deal with psoriasis...

"The first step in managing psoriasis is to visit a dermatologist. Whilst psoriasis is not curable, there are a multitude of treatment options to help control the disease and improve symptoms. Topical steroids, UV therapy and the newer biologics such as Enbrel are examples of some of the therapies available."

ADVERTISEMENT - CONTINUE READING BELOW

"Alcohol or acid-based ingredients (glycolic, salicylic and lactic acid) which can be found in soaps, moisturisers and deodorants, can cause irritation and inflammation."

Getty RUTH JENKINSON

"Keeping a daily diary can helpful in monitoring psoriasis flare-ups. Stress levels, diet, exercise, skin products, medications, exposure to sunlight, and sleep and hydration levels may all play a role. Reviewing a daily diary with your skin specialist may help you better understand and manage the condition."

"Stress is a common trigger for psoriasis. Meditating, yoga, acupuncture and exercise are all effective ways to help reduce stress. Also try to ensure you are getting adequate sleep."

"A well-rounded diet including fruits, vegetables, whole grains, fish and monounsaturated fats may help reduce psoriasis flare-ups. For some patients supplements containing omega 3 fatty acids such as fish oil and flaxseed may also be helpful, but it is advisable to speak with a medical professional before introducing nutritional supplements into your diet."

Related Article

5 hidden links between illnesses you should be aware of

"Both smoking and excessive drinking may make psoriasis significantly worse."

"Applying emollients regularly helps prevent new psoriatic plaques forming and may reduce reduce itching."

"UV exposure helps reduce psoriasis symptoms, but over-exposure can have a detrimental effect on the skin and increases the risk of skin cancer. Always use sun cream to protect your skin and talk to your healthcare professional about the possibility of in-office or home UV treatment."

Link:

8 ways to manage psoriasis - Netdoctor

If you have psoriasis, you already know that smart lifestyle strategies(such as managing stress, not using harsh soaps, and avoiding certain foods)may help keep symptoms at bay. But one of the most important things you can do to keep the skin condition under control might be to shed extra pounds. Here, five reasons why it's so crucial for psoriasis patients to watch their weight.

Psoriasis is an autoimmune disease, which means the immune system attacks a part of the body (in this case, the skin). The result is raised red, white, or silvery patches on the skin, as well as other possible symptoms such as itching, nail disfigurement, or dry, cracked skin. Psoriasis is a chronic condition, meaning you have it for your entire lifebut weight loss may alleviate some of the symptoms.

"Studies show that diet and exercise canreduce symptoms of psoriasis," says Debra Jaliman, MD, a dermatologist based in New York City.In a recent Danish study published inAmerican Journal of Clinical Nutrition, obese psoriasis participants who lost 10% to 15% of their body weight showed significant improvement in symptoms. What's more, the improvement was long-lasting: a year after the study ended, the participants who lost at least 22 pounds from their start weightcontinued to experience improved quality of life.

RELATED: Kim Kardashian Says Her Psoriasis Is 'Part of Who I Am'

About 10% to 30% of psoriasis patients eventually develop psoriatic arthritis, an autoimmune disease that causes painful, swollen joints. But overweight or obese psoriasis patients may be particularly at risk.In a study published in the journalAnnals of the Rheumatic Diseases, researchersfound a link between obesityand increased chance of developing the condition. The study looked at data collectedovera 15-year period of more than 75,000 people in the UK, and found that psoriatic arthritis incidence rates increased along with BMI.

If you're a psoriasis patient who also has psoriatic arthritis, extraweight can strainyour joints, which may aggravate symptoms.Psoriatic arthritis can affect both smaller joints (think: fingers, toes, wrists) as well aslarge, weight-bearing ones like your kneesand added pounds can put unnecessary pressure on them, making symptoms worse.

"No matter what type of arthritis you have, weight is particularly bad for weight-bearing joints, the hips and knees in particular," says James R. ODell, MD, chief of rheumatology at the University of Nebraska Medical Center in Omaha.

Research appears to backthis up:In 2014, Canadian researchers found that obese psoriatic arthritis patients were less likely to achieve a state of remission than those with lower BMIs.

RELATED: 9 Things People With Psoriatic Arthritis Want You to Know

One reasonwhy obese psoriatic arthritis patients may be less likely to achieve remission? Overweight and obese people dont always respond as well to medications used to treat the disease, according to the Arthritis Foundation.

"You have this perfect storm," says Dr. ODell. "Youre more likely to have problems and to have less response to medication."

Losing weight may help medications work more effectively for both psoriatic arthritis and psoriasis.In a 2014 study of obesepsoriasispatients, researchers found that losing weight helped increase the efficacy of biologic drugtreatments.

RELATED: The 12 Best and Worst Foods for Psoriasis

As an added incentive to slim down, losing weight can also reduce your odds of heart disease, diabetes, and strokeconditions that both psoriasis and psoriatic arthritis patients have an elevated risk of developing.

Dr. ODell explains that he encourages all of his patients to get to (and maintain) a healthy body weight. But this isespecially true for those with conditions like psoriatic arthritis and psoriasis.

For them, "weight loss is doubly important," he says."I would say that to about anybody, [but] sometimes people need another reason or an over-and-above reason [to lose weight]."

Continue reading here:

Why Your Weight Matters If You Have Psoriasis - Health.com

Anyone who has psoriasis knows just how uncomfortable it can be. The skin condition, which is actually an autoimmune disease, occurs when skin cells grow and appear on the outer surface of the skin at an accelerated rate. The result? Raised patches of dry red, white, or silvery skin that can feel itchy or even painful.

What most people dont realize is that there are five different forms of the chronic disease, the most common of which is called plaque psoriasis. But what actually causes the uncomfortable condition? While its not entirely clear, its possible that a family history of the disease, as well as lifestyle factors like smoking and obesity, can raise ones risk of psoriasis.

While you may not be able to do anything about your familys genetics, you can certainly take smart steps to stay healthy and lower your risk of psoriasis. For one, ditch your cigarette habit stat. Next, eat the right kinds of foods to keep your body at a healthy weight.

RELATED: Can a Healthy Diet Help Psoriasis?

Not sure which foods will best serve you (pun intended)? Weve got you covered. In this video, we show you the best and worst foods to eat if you have psoriasis.

From fish thats filled with healthy omega-3 fatty acids (like salmon, mackerel, and sardines) to fiber-rich whole grains and antioxidant-heavy blueberries, were highlighting the foods you should put on your plate, plus ones to leave behind at the grocery store, if you have psoriasis.

See original here:

The Best and Worst Foods for Psoriasis - Psoriasis - Health.com Video - Health.com

Secukinumab does not increase IBD incidence in patients with psoriasis, spondyloarthropathies Healio Reports of Crohn's disease and ulcerative colitis among patients with psoriasis, psoriatic arthritis or ankylosing spondylitis treated with secukinumab were infrequent and consistent with earlier findings, according to data presented at the American ...

Read the original post:

Secukinumab does not increase IBD incidence in patients with psoriasis, spondyloarthropathies - Healio